Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

20150924 smb biosenz johan oosterheert


Published on

Presentation Science Meets Business @Health Valley From Molecule to Business 20150924

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

20150924 smb biosenz johan oosterheert

  1. 1. Biosenz B.V. – A Lavoisier Company - Zernikepark 16 9747AN Groningen – 050 8508960- - ViriChip™ System: A platform technology for virus detection and identification Johan Oosterheert, Managing director September 24, 2015
  2. 2. 9/28/2015 Strictly confidential New 'Sars-like' coronavirus identified by UK officials By Michelle Roberts Health editor, BBC News online, September 2012 A new respiratory illness similar to the Sars virus that spread globally in 2003 and killed hundreds of people has been identified in a man who is being treated in Britain. The 49-year-old man, who was transferred to a London hospital by air ambulance from Qatar, is the second person confirmed with the corona virus. The first case was a patient in Saudi Arabia who has since died. Officials are still determining what threat the new virus may pose. Infectious viruses pose a serious threat to public health • Current diagnostic systems for viruses use central labs • Identification may take several days
  3. 3. ViriChip™ shortens response time dramatically 9/28/2015 Strictly confidential The ViriChip™ System brings the Lab to the field! The ViriChip™ System: • Size of a shoe box • On-the-spot detection and identification • 30 minutes response time
  4. 4. ViriChip™ is a unique, patented lab-on-a chip technology 9/28/2015 Strictly confidential Nano - and Biotechnology Atomic Force Microscopy Ligand capture Biosenz holds exclusive world-wide license on several patents
  5. 5. Biosenz has validated the technology 9/28/2015 Strictly confidential Silicon chip including antibodies with Coxsackie B3 virus attached Biosenz has validated 15 different viruses
  6. 6. ViriChip offers sensitivity, specificity, ease of use and speed 9/28/2015 Strictly confidential ViriChip PCR Immuno assays Immuno electron Microscopy Cell culture RAMP Response time Integral cost/test Sensitivity Specificity Portability Ease of use Bulk processing
  7. 7. Biosenz intends to sell Virichip in multiple markets 9/28/2015 Strictly confidential 1 2 3 4 5 6 7 8 Veterinary Food Clinical Markets CDC, Homeland Security, Defense Research Institutes US Bio-defense busget $ 6.4 Bln. In 2012 World In-vitro diagnostic market $ 40 Bln. (2010) POCT for infectious diseases $ 843 M (2011); 14% CAGR
  8. 8. Biosenz operates as a network organization 9/28/2015 Strictly confidential
  9. 9. ViriChip presents a unique opportunity • Current diagnostic methods used to identify viruses use central labs and take days • ViriChip technology brings the lab to the field, reducing response time to ~30 minutes • Significant market potential • Limited risk through business model and team 9/28/2015 Strictly confidential
  10. 10. Thank you for your attention. 9/28/2015 Strictly confidential